Psychedelic Alpha’s Josh Hardman speaks with Robert Schoevers, Head of Psychiatry at University Medical Center Groningen and principal investigator of the EU-funded PsyPal study, about growing public investment in psychedelic research across Europe. They discuss new EU and national initiatives, the Netherlands’ pragmatic approach, and why Schoevers describes himself as a “hopeful skeptic” when it comes to psychedelic therapies.
